CMS launched details of the Medicare GLP-1 Bridge program, creating a flat $50 monthly copay signal for eligible Medicare Part D beneficiaries seeking certain weight management drugs through a time-limited federal framework running through Dec. 31, 2027. The program is designed to operate outside traditional Part D coverage and payment mechanics, separating access from standard benefit flow. Major pharmacies—CVS, Walgreens, Amazon Pharmacy and Publix—aligned quickly with services around the Bridge’s unified prior authorization and claims handling infrastructure. Manufacturers are positioning products within the framework, including Novo Nordisk and Eli Lilly’s weight-loss brands, while the program excludes Medicare patients with type 2 diabetes. For biotech and pharma, the Bridge effectively redraws the economics of launching and sustaining obesity drug access in older populations by making pricing predictable and shifting implementation burdens toward a centralized CMS administrative pathway.